MarketCap
Facebook
X
TelegramAnnual report 2026
added 02-10-2026
Exelixis Operating Cycle 2011-2026 | EXEL
Annual Operating Cycle Exelixis
| 2026 | 2025 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 140 | - | 172 | 248 | 190 | 142 | 187 | 213 | 227 | 245 | 296 | 496 | 989 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 989 | 140 | 295 |
Quarterly Operating Cycle Exelixis
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 171 | 159 | 157 | - | 166 | 153 | 134 | - | 177 | 196 | 252 | - | 228 | 254 | 254 | 78.1 | 253 | 194 | 180 | 54.1 | 245 | 204 | 103 | - | 201 | 175 | 179 | 65 | 188 | 230 | 171 | 38.2 | 181 | 74.8 | 68.6 | 77.4 | 96.6 | 102 | 135 | 47.6 | 48 | 59.2 | 48.9 | 60.6 | 70.8 | 67.9 | 82.1 | 82.7 | 65.8 | 30.3 | 31.6 | 32.1 | 18.9 | 32.1 | 6.78 | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 254 | 6.78 | 125 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
50 | $ 4.5 | 0.45 % | $ 862 M |  Canada |
 |
Agenus
AGEN
|
3.58 | $ 3.64 | 9.31 % | $ 108 M |  USA |
 |
Agios Pharmaceuticals
AGIO
|
1.74 K | $ 35.08 | -0.36 % | $ 2.03 B | USA |
 |
Akebia Therapeutics
AKBA
|
210 | $ 1.39 | 0.36 % | $ 357 M | USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
102 | $ 331.14 | 3.85 % | $ 43.4 B | USA |
 |
Altimmune
ALT
|
7.85 K | $ 3.4 | 1.8 % | $ 300 M | USA |
 |
Amgen
AMGN
|
282 | $ 344.03 | -1.12 % | $ 185 B | USA |
 |
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
117 | $ 12.27 | -1.68 % | $ 3.85 B | USA |
 |
Anika Therapeutics
ANIK
|
325 | $ 14.99 | 1.28 % | $ 220 M | USA |
 |
Acorda Therapeutics
ACOR
|
394 | - | -24.86 % | $ 820 K | USA |
 |
ANI Pharmaceuticals
ANIP
|
295 | $ 73.8 | -0.55 % | $ 1.43 B | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Aptorum Group Limited
APM
|
4.89 | $ 0.88 | -5.16 % | $ 4.8 M | China |
 |
Aquestive Therapeutics
AQST
|
223 | $ 4.12 | -0.24 % | $ 441 M | USA |
 |
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
21.2 | $ 8.14 | 1.31 % | $ 223 M |  Israel |
 |
Ardelyx
ARDX
|
1.05 K | $ 5.99 | 0.84 % | $ 1.44 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Arcutis Biotherapeutics
ARQT
|
291 | $ 24.06 | 1.82 % | $ 3.06 B | USA |
 |
Arvinas
ARVN
|
4.66 | $ 10.87 | 0.14 % | $ 771 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
8.75 | $ 60.28 | -1.23 % | $ 8.06 B | USA |
 |
Assembly Biosciences
ASMB
|
25.1 | $ 29.51 | 1.72 % | $ 331 M | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |